Introduction
Podophyllin resin remains one of the most common first line agents in the treatment of anogenital condylomata' despite the problems of incomplete response and frequent recurrence. Currently available chemical and physical ablative methods aim to remove clinically visible condylomata. Apparently normal epithelium may harbour latent human papillomavirus (HPV) infection which may be responsible for the high incidence of recurrent disease. The known antiviral and immunomodulatory properties of interferons make these agents a theoretically attractive systemic adjuvant treatment in conjunction with standard ablative procedures to treat such latent infection. Interferon treatment involves considerable expense and is associated with characteristic adverse effects and accordingly an improved response rate in combination with cheaper and more practical first line alternatives should be demonstrated before more widespread use could be recommended. The current study was designed with the primary objective of comparing the efficacy of combination treatment with podophyllin and systemic interferon alpha-2a (IFN) versus podophyllin and placebo for the treatment of primary anogenital condylomata and secondly to compare recurrence rates in the two treatment groups over a six month follow-up period.
Patients and methods
This study was conducted in six genitourinary clinics within the United Kingdom after study approval was obtained from each local medical ethics committee.
Patient selection
Patients aged years of age with clinically visible condylomata acuminata of the external genitalia and/or perianal area for less than six months with no history of previous treatment were eligible for study entry. Patients had to give wimessed oral or written informed consent, be able and willing to conform with the requirements of the study and be HIV antibody negative. Patients were excluded if they had internal genital or anal canal lesions only, had any single lesion more than 3 cm in greatest diameter, had a history of previous immunosuppressive or immunomodulatory therapy (including interferon) or had any condition associated with immunodeficiency. In addition, patients were excluded if they had any evidence of malignant neoplastic disease (except carcinoma-in-situ of the cervix or localized basal cell carcinoma), had an acute sexually transmitted disease, were Weekly assessments were performed immediately prior to the second administration of IFN/placebo and podophyllin during weeks 1-6 to document the lesion count and disease status as defined in table 1.
A week 10 assessment of lesion count and disease status was performed in all patients. A week 26 assessment of disease status was performed for all patients demonstrating a complete response at week 10. In each case if a recurrence had occurred, a biopsy was taken and an HIV test performed.
At each assessment the nature, duration, severity and relation to treatment of any adverse events were recorded and any treatments given documented.
Laboratory investigations
Blood was taken for haemoglobin concentration, white blood cell count, platelet count, creatinine and AST during the pre-study screen, at the end of week 6 and at the week 10 assessment. In the event of unexplained or unexpected test value abnormalities, the tests were repeated immediately and followed up until the results returned to the normal range and/or an adequate explanation of the abnormality was found.
Withdrawal criteria Criteria for patient withdrawal included pregnancy, missing one or more of the pretreatment injections, missing one week's combination treatment, progressive disease, which in the investigator's opinion required alternative treatment, deliberate or accidental breaking of the treatment code, any adverse event severe enough, in the investigator's opinion, to warrant discontinuation of treatment, loss of patient to follow-up or at the request of the patient.
Statistical analysis Sample size was calculated to detect a 30% difference in response rates between placebo and IFN treated groups with 80% power using a two-sided test at the 5% level of significance. The primary efficacy analysis was an evaluation of the week 10 assessment of disease and was compared between treatments using logistic regression methods. The secondary efficacy analysis comprised logistic regression of the week 26 data, namely recurrence or not.
Results
In total, 124 patients were recruited at six centres. Sixty-one patients were randomised to receive IFN plus podophyllin (IFN group) (table 7) .
Caution, however, must be exercised in interpreting the results of analysis of week 26 data as it was based on a non-randomised and Statistical analysis of our week 26 data must be viewed with caution because of the previously described bias but suggested no significant benefit of adjunctive IFN therapy on recurrence rates. Analysis of pre-treatment characteristics predictive of clinical outcome at week 10 showed no significant effect on complete response of duration of disease, sex, number of lesions, type of lesions or the presence of internal lesions in keeping with previous reports.'8 Several studies have, however, shown a poorer response with longer duration of disease,'4 male sex'0 14 and with large numbers of lesions. 015 19 In summary we conclude that at the dose and with the regime described combination therapy with systemic IFN alpha-2a and podophyllin is no more efficacious than podophyllin alone in terms of complete response or recurrence in patients with primary anogenital condylomata acuminata.
